Drug-resistant HER2-positive Breast Cancer: Molecular Mechanisms and Overcoming Strategies

Overview

Journal Front Pharmacol

Date 2022 Oct 10

PMID 36210846

Authors

Xiaofan Wu

Hongjian Yang

Xingfei Yu

Jiang-Jiang Qin

Affiliations

Soon will be listed here.

Abstract

Breast cancer is one of the most common malignancies and the leading cause of cancer-related death in women. HER2 overexpression is a factor for poor prognosis in breast cancer, and anti-HER2 therapy improves survival in these patients. A dual-targeted combination of pertuzumab and trastuzumab, alongside cytotoxic chemotherapy, constitutes the primary treatment option for individuals with early-stage, HER2-positive breast cancer. Antibody-drug conjugate (ADC) and tyrosine kinase inhibitors (TKI) also increase the prognosis for patients with metastatic breast cancer. However, resistance to targeted therapy eventually occurs. Therefore, it is critical to investigate how HER2-positive breast cancer is resistant to targeted therapy and to develop novel drugs or strategies to overcome the resistance simultaneously. This review aims to provide a comprehensive discussion of the HER2-targeted agents currently in clinical practice, the molecular mechanisms of resistance to these drugs, and the potential strategies for overcoming resistance.

Citing Articles

Heterogeneity in Cancer.

MacDonald W, Purcell C, Pinho-Schwermann M, Stubbs N, Srinivasan P, El-Deiry W Cancers (Basel). 2025; 17(3).

PMID: 39941808 PMC: 11816170. DOI: 10.3390/cancers17030441.

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.

Scalambra L, Ruzzi F, Pittino O, Semprini M, Cappello C, Angelicola S J Transl Med. 2025; 23(1):136.

PMID: 39885551 PMC: 11784117. DOI: 10.1186/s12967-025-06126-w.

Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer.

Lee J, Song J, Yoo W, Choi H, Jung D, Choi E Cancer Immunol Immunother. 2025; 74(2):73.

PMID: 39751931 PMC: 11698710. DOI: 10.1007/s00262-024-03923-y.

Mechanism of miRNAs and miRNA-mRNA Regulatory Networks in Modulating Drug Resistance in HER2-Positive Breast Cancer: An Integrative Bioinformatics Approach.

Vo T, McNeela E, ODonovan O, Rani S, Mehta J Cancers (Basel). 2024; 16(23).

PMID: 39682150 PMC: 11640410. DOI: 10.3390/cancers16233962.

Resistance mechanisms and prospects of trastuzumab.

Wang L, Wang Y, Li Y, Zhou L, Du J, Wang J Front Oncol. 2024; 14:1389390.

PMID: 39655080 PMC: 11625751. DOI: 10.3389/fonc.2024.1389390.

References

Pietras R, Pegram M, Finn R, Maneval D, Slamon D . Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998; 17(17):2235-49. DOI: 10.1038/sj.onc.1202132. View

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Junttila T, Li G, Parsons K, Phillips G, Sliwkowski M . Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2010; 128(2):347-56. DOI: 10.1007/s10549-010-1090-x. View

Ribas A . Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 2015; 5(9):915-9. PMC: 4560619. DOI: 10.1158/2159-8290.CD-15-0563. View

Franklin M, Carey K, Vajdos F, Leahy D, de Vos A, Sliwkowski M . Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5(4):317-28. DOI: 10.1016/s1535-6108(04)00083-2. View

Fruman D, Chiu H, Hopkins B, Bagrodia S, Cantley L, Abraham R . The PI3K Pathway in Human Disease. Cell. 2017; 170(4):605-635. PMC: 5726441. DOI: 10.1016/j.cell.2017.07.029. View

Chung Y, Kuo J, Wei W, Chang K, Chao W . Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). PLoS One. 2015; 10(7):e0133072. PMC: 4501549. DOI: 10.1371/journal.pone.0133072. View

Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R . Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021; 6(1):236. PMC: 8219715. DOI: 10.1038/s41392-021-00629-w. View

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

10.

Tolaney S, Tayob N, Dang C, Yardley D, Isakoff S, Valero V . Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021; 39(21):2375-2385. DOI: 10.1200/JCO.20.03398. View

11.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

12.

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini P . Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010; 16(9):2688-95. PMC: 3243489. DOI: 10.1158/1078-0432.CCR-09-3407. View

13.

Goss P, Smith I, OShaughnessy J, Ejlertsen B, Kaufmann M, Boyle F . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2012; 14(1):88-96. DOI: 10.1016/S1470-2045(12)70508-9. View

14.

Zheng G, Jia L, Yang A . Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment. Front Immunol. 2022; 13:791975. PMC: 8850630. DOI: 10.3389/fimmu.2022.791975. View

15.

Collins D, ODonovan N, McGowan P, OSullivan F, Duffy M, Crown J . Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2011; 23(7):1788-95. DOI: 10.1093/annonc/mdr484. View

16.

Fernandez-Martinez A, Krop I, Hillman D, Polley M, Parker J, Huebner L . Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020; 38(35):4184-4193. PMC: 7723687. DOI: 10.1200/JCO.20.01276. View

17.

Swain S, Miles D, Kim S, Im Y, Im S, Semiglazov V . Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4):519-530. DOI: 10.1016/S1470-2045(19)30863-0. View

18.

Bachman K, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S . The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004; 3(8):772-5. DOI: 10.4161/cbt.3.8.994. View

19.

Majewski I, Nuciforo P, Mittempergher L, Bosma A, Eidtmann H, Holmes E . PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 2015; 33(12):1334-9. PMC: 5087318. DOI: 10.1200/JCO.2014.55.2158. View

20.

Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney Jr D . Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421(6924):756-60. DOI: 10.1038/nature01392. View